Revelation Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $4.5M
- Price
- $1.11
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.05%
- Volume
- 166.5K
About
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Quick stats
Shares outstanding3.9M
Computed float10.1M
Float / shares259.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001810560
AI Summary
AI-generated1/9
standardbullishclinical trial
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
Revelation Biosciences selected Avance Clinical as the contract research organization for its Phase 2/3 adaptive-design TITAN study.
The trial will evaluate the company's proprietary formulation, Gemini, as a treatment for patients with acute kidney injury.
Management confirmed that the study is on track to begin later this year, marking a significant advancement in the company's clinical pipeline.